A Cheshire-based startup developing an AI platform for the rapid diagnosis of cancer has secured a £425,000 investment.
Spotlight Pathology said the capital injection – which is part of a planned £1.1m round it aims to close mid-year – would allow it to finish the development of its blood cancer diagnostic platform as it seeks regulatory approval in the UK, Europe and the US.
Blood cancer is among the most common forms of the disease in the UK, with around 40,000 diagnoses annually according to Blood Cancer UK.
Spotlight Pathology has warned that workforce shortages and increased demand for services has slowed down essential cancer care.
The startup is one of many turning to artificial intelligence as a possible solution. The company said its machine learning technology can integrate with existing pathology infrastructure to minimise diagnosis turnaround times and alleviate clinician workloads.
“There’s a critical shortage of pathologists, and the stakes are high—delayed diagnosis means delayed treatment. Our platform gives clinicians the tools to confidently streamline diagnostic workflows,” said Spotlight Pathology chief executiveDr. Sam Perona.
“This investment is a major step forward in bringing our technology to market and improving outcomes for people affected by blood cancers.”
The funding came from EHE Venture Studio’s AI Growth Fund with support from DeepBridge Capital and Lyva Labs.
“Spotlight is exactly the kind of company our fund was built to support – founder-led, mission-driven, and applying AI to solve one of the most urgent challenges in global healthcare,” said EHE Venture Studio’s Neil Vose.
“We are not just providing capital. Through our Venture Studio, we’ll be working alongside Sam and the team to scale the platform, accelerate development, and prepare for market entry.”
Spotlight Pathology previously secured a £125,000 investment from Lyva Labs last year.
Register for Free
Bookmark your favorite posts, get daily updates, and enjoy an ad-reduced experience.
Already have an account? Log in
